Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Deloitte
Moodys
Cipla
Julphar
Fish and Richardson
Boehringer Ingelheim
Baxter
Farmers Insurance

Generated: April 19, 2018

DrugPatentWatch Database Preview

NOVANTRONE Drug Profile

« Back to Dashboard

Which patents cover Novantrone, and what generic alternatives are available?

Novantrone is a drug marketed by Emd Serono and is included in one NDA.

The generic ingredient in NOVANTRONE is mitoxantrone hydrochloride. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mitoxantrone hydrochloride profile page.
Drug patent expirations by year for NOVANTRONE
Medical Subject Heading (MeSH) Categories for NOVANTRONE
Synonyms for NOVANTRONE
1,4-dihydroxy-5,8-bis-[[2-(2-hydroxyethylamino)ethyl]amino]-anthraquinone dihydrochloride
1,4-Dihydroxy-5,8-bis-[2-(2-hydroxy-ethylamino)-ethylamino]-anthraquinone dihydrochloride
1,4-dihydroxy-5,8-bis-[2-(2-hydroxyethylamino)ethylamino]anthraquinone 2hcl
1,4-Dihydroxy-5,8-bis-[2-(2-hydroxyethylamino)ethylamino]anthraquinone dihydrochloride
1,4-dihydroxy-5,8-bis-[2-(2-hydroxyethylamino)ethylamino]anthraquinonedihydrochloride
1,4-Dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino-ethyl)amino)anthraquinone dihyrochloride
1,4-Dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione dihydrochloride
1,4-Dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthraquinone dihydrochloride
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione dihydrochloride
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione dihydrochloride
1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone dihydrochloride
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone dihydrochloride
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione dihydrochloride
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;dihydrochloride
271M809
65271-80-9 (Parent)
70476-82-3
70476-82-3,65271-80-9(freebase),70711-41-0(diacetate)
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-, dihydrochloride
AB0013075
AB2000351
AC-1591
AC1L1AED
AC1Q3B38
ACMC-20enxy
AK163016
AKOS015895228
AS-13162
BC215535
BCP0726000265
BCP9000932
Bisantrone
C22H28N4O6.2HCl
C22H30Cl2N4O6
CAS-70476-82-3
CCG-39938
CCRIS 2592
CHEBI:50727
CHEMBL1417019
CL 232,315
CL 232315
CL-232315
CS-2525
CTK8F1285
D02166
DHAD
dhaq dihydrochloride 65271-80-9
DR003135
DSSTox_CID_25173
DSSTox_GSID_45173
DSSTox_RID_80722
DTXSID0045173
EINECS 274-619-1
Eslep
EU-0100779
H492
HMS1569M11
HMS1922O21
HSDB 6543
HY-13502A
I06-0260
Immunex
KS-00000XLU
LP00779
LS-20325
M 6545
MFCD00242943
mitoxanthrone hcl
MITOXANTHRONE HYDROCHLORIDE
Mitoxantrone (dihydrochloride)
Mitoxantrone Dihcl
Mitoxantrone dihydrochloride
Mitoxantrone dihydrochloride, >=97% (HPLC)
Mitoxantrone HCl
Mitoxantrone hydrochloride
Mitoxantrone hydrochloride (JAN/USP)
Mitoxantrone hydrochloride [USAN:JAN]
Mitoxantrone hydrochloride, European Pharmacopoeia (EP) Reference Standard
Mitoxantrone hydrochloride, United States Pharmacopeia (USP) Reference Standard
Mitozantrone hydrochloride
Mitroxantrone Hydrochloride
MolPort-003-665-506
NCGC00015693-02
NCGC00015693-09
NCGC00094116-01
NCGC00094116-02
NCGC00094116-03
NCGC00094116-04
NCGC00261464-01
Novantron
Novantron (TN)
novatrone
NSC 301739
NSC-301739
NSC-310739
NSC-310739;Novantrone
Onkotrone
Prestwick_571
Ralenova
s2485
SCHEMBL3928
SPECTRUM1503278
SR-01000076001
SR-01000076001-1
ST24048109
ST51052724
TL8004973
Tox21_110197
Tox21_110197_1
Tox21_500779
TX-017757
U6USW86RD0
UNII-U6USW86RD0
W-104553
X-2300
Z2569867923
ZAHQPTJLOCWVPG-UHFFFAOYSA-N

US Patents and Regulatory Information for NOVANTRONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono NOVANTRONE mitoxantrone hydrochloride INJECTABLE;INJECTION 019297-001 Dec 23, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono NOVANTRONE mitoxantrone hydrochloride INJECTABLE;INJECTION 019297-002 Dec 23, 1987 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono NOVANTRONE mitoxantrone hydrochloride INJECTABLE;INJECTION 019297-003 Dec 23, 1987 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NOVANTRONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono NOVANTRONE mitoxantrone hydrochloride INJECTABLE;INJECTION 019297-001 Dec 23, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono NOVANTRONE mitoxantrone hydrochloride INJECTABLE;INJECTION 019297-001 Dec 23, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono NOVANTRONE mitoxantrone hydrochloride INJECTABLE;INJECTION 019297-001 Dec 23, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono NOVANTRONE mitoxantrone hydrochloride INJECTABLE;INJECTION 019297-001 Dec 23, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Citi
Fuji
Deloitte
Covington
Chinese Patent Office
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.